Ultime notizie per BTC Digital (NASDAQ:BTCT) Azioni

BTC Digital

Meten Holding Gr

BTC Digital Ltd is a crypto asset technology company based in the U.S. with a focus on bitcoin mining. The company also generates revenue through mining machine resale and rental business operations. Geographically, the financial assets of the company is located in the United States, Singapore, Hong Kong and the PRC.

BTC Digital Ltd

Bitcoin - TrueUSD

BTC Digital Ltd Warrants (31/03/2025)

Earnings

Earnings Misses

News

CBIO

Crescent Biopharma Q2 EPS $(4.93) Misses $(1.11) Estimate, Cash Balance Of $152.6M

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Brown &amp; Brown (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRO#NYSE">BRO</a>) with a Underperform and lowers the price target from $104 to $87.

Price Target

Analyst Ratings

Keefe, Bruyette & Woods Maintains Underperform on Brown & Brown, Lowers Price Target to $87

RGEN

Repligen Partners With Novasign To Advance Digital Twins And Predictive Process Control For Bioprocessing Workflows

Vanda Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) affirms FY2025 sales outlook from $210.00 million-$250.00 million to $210.00 million-$250.00 million vs $227.72 million estimate.

Guidance

VNDA

Vanda Pharmaceuticals Affirms FY2025 Sales Guidance of $210.00M-$250.00M vs $227.72M Est

PRINCETON, N.J., July 31, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need,&nbsp;announced today that it has completed its Phase 2a proof of concept study evaluating SGX945 (dusquetide) in the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4478637-1&amp;h=3362255736&amp;u=https%3A%2F%2Fwww.soligenix.com%2Fpipeline-programs%2Fsgx945-for-aphthous-ulcers-of-behcets-disease%2F&amp;a=treatment+of+Beh%C3%A7et%27s+Disease">treatment of Behçet's Disease</a> and achieved the study objective of demonstrating biological efficacy.

Biotech

General

SNGX

Soligenix Completes Phase 2a Proof Of Concept Study Evaluating SGX945 In Behçet's Disease, Showing Biological Efficacy

Needham analyst John Todaro maintains Applied Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) with a Buy and raises the price target from $12 to $16.

APLD

Needham Maintains Buy on Applied Digital, Raises Price Target to $16

EDBL

Edible Garden Launches First USDA Organic Hydroponic Basil, Advancing Sustainability And Leadership In Controlled Environment Agriculture

Keefe, Bruyette &amp; Woods analyst Kelly Motta maintains Axos Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AX#NYSE">AX</a>) with a Market Perform and raises the price target from $90 to $94.

Keefe, Bruyette & Woods Maintains Market Perform on Axos Financial, Raises Price Target to $94

Vanda Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.36) by 28.85 percent. This is a 475 percent decrease over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $52.59 million which missed the analyst consensus estimate of $54.60 million by 3.68 percent. This is a 4.19 percent increase over sales of $50.47 million the same period last year.

Vanda Pharma Q2 EPS $(0.46) Misses $(0.36) Estimate, Sales $52.59M Miss $54.60M Estimate

<ul>
<li>CNSide available for the state of Texas in August 2025</li>
<li>Initial commercial focus on NCI-Designated Cancer Centers and large private healthcare systems</li>
<li>Company will expand testing services and broaden regional availability over the next 12 months</li>
</ul>

PSTV

Plus Therapeutics Launches CNSide Diagnostic In Texas With Initial Focus On NCI-Designated Cancer Centers

Psyence BioMed And PsyLabs Achieve Breakthrough In GMP-Aligned High-Purity Ibogaine Production For Global Psychedelic API Supply

Needham analyst James Ricchiuti maintains Impinj (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>) with a Buy and raises the price target from $115 to $165.

Needham Maintains Buy on Impinj, Raises Price Target to $165

Lantern Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR&#xAE; AI platform, today announced the successful completion of targeted enrollment for its Phase 2 HARMONIC&#x2122; clinical trial in Japan. The company enrolled 10 patients ahead of schedule across five clinical sites in Japan, including the National Cancer Center Japan.
The HARMONIC&#x2122; trial is evaluating LP-300 in combination with carboplatin and pemetrexed in never-smoker patients with non-small cell lung cancer (NSCLC) who have progressed after receiving treatment with tyrosine kinase inhibitors (TKIs). The successful Japanese enrollment validates Lantern's strategic decision to expand the trial internationally to regions with significantly higher rates of never-smoker NSCLC patients such as Japan and Taiwan.

LTRN

Lantern Pharma Completes Early Enrollment in Japan for Lung Cancer Trial Targeting Never-Smokers

Keefe, Bruyette &amp; Woods analyst Ryan Tomasello upgrades AppFolio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPF#NASDAQ">APPF</a>) from Underweight to Market Perform and raises the price target from $205 to $267.

Upgrades

APPF

Keefe, Bruyette & Woods Upgrades AppFolio to Market Perform, Raises Price Target to $267

Hilton Grand Vacations Reiterates FY25 Adjusted EBITDA Guidance Of $1.125B-$1.165B

Agreement strengthens&nbsp;ATI's role as leading aerospace structures supplier
 &nbsp;

Boeing Taps ATI For Long-Term Titanium Supply Across Narrowbody And Widebody Programs, Including Third-Party Subsidiaries

PPL (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPL#NYSE">PPL</a>) reported quarterly earnings of $0.32 per share which missed the analyst consensus estimate of $0.39 by 17.31 percent. This is a 15.79 percent decrease over earnings of $0.38 per share from the same period last year. The company reported quarterly sales of $2.025 billion which beat the analyst consensus estimate of $1.986 billion by 1.94 percent. This is a 7.66 percent increase over sales of $1.881 billion the same period last year.

Earnings Beats

CORRECTION: PPL Q2 Adj. EPS $0.32 Misses $0.39 Estimate, Sales $2.025B Beat $1.986B Estimate

ATI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATI#NYSE">ATI</a>) narrows FY2025 Adj EPS guidance from $2.87-$3.09 to $2.90-$3.07 vs $2.99 analyst estimate..

ATI Narrows FY2025 Adj EPS Guidance from $2.87-$3.09 to $2.90-$3.07 vs $2.99 Est

Needham analyst Mike Cikos maintains Confluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) with a Buy and lowers the price target from $26 to $24.

CFLT

Needham Maintains Buy on Confluent, Lowers Price Target to $24

ATI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATI#NYSE">ATI</a>) is looking for Q3 Adj EPS of $0.69-$0.75 vs $0.75 analyst estimate..

Comments

BTC Digital

Notizie

Ultime notizie per BTC Digital (NASDAQ:BTCT) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO